Therapeutic Pipeline
May 2025

Product Name	Indication	Modality	Mechanism of Action	Target Validation	Hit to Lead	Lead	Pre-clinical	Clinical	Market
Oncology									
Targeting NKp44/ PDGF-D axis	Cancer	Biologic	Novel NK-focused immune checkpoint target for cancer therapy.						
Novel method of PD1/PDL1 axis modulation	Cancer	TBC	Novel method of PD1/PDL1 axis modulation by targeting “Factor X” protein on the surface of monocytes.						
Infectious Disease									
Ultra-potent and broadly neutralising anti-HIV antibodies	HIV	Biologic	CD4 binding site						
Method(s) of conferring antibiotic sensitivity to antibiotic resistant bacteria	Antibiotic resistance	Small molecule	Confidential						
Metabolic Disease									
mRNA therapies for diabetes and obesity treatment	Diabetes and obesity	mRNA	Confidential						
Inflammation, Fibrosis and Autoimmune									
Novel therapeutics for systemic lupus erythematosus (SLE)	Systemic Lupus Erythematosus (SLE)	Small molecule and cyclic peptide	Confidential						
Women’s Health									
Targeted nanomedicine for treatment of placental dysfunction	Preeclampsia	siRNA	Confidential						

For further information regarding any of these assets, please contact the Knowledge and Technology Transfer team:
go.unimelb.edu.au/za4p | ip-mailbox@unimelb.edu.au

Therapeutic Pipeline
May 2025

Product Name	Indication	Modality	Mechanism of Action	Target Validation	Hit to Lead	Lead	Pre-clinical	Clinical	Market
COVID-19									
Inhibitor of SARS-CoV2	COVID-19	Small molecule	Confidential						
Chimeric trimeric RBD (CTR) COVID vaccine	COVID-19	Vaccine	A highly immunogenic second generation COVID-19 vaccine strategy to overcome imprinted immune response issues.						
SARS-CoV2 virus like particle (VLP) vaccine	COVID-19	Vaccine	Multigene variant proof vaccine for long lasting memory and neutralising antibody response.						
Monoclonal antibodies against COVID-19	COVID-19	Biologic	Confidential						

Technology Platforms

Product Name	Application	Up to Experimental Proof of Concept (TRL 1-3)	Technology Demonstration / Prototype (TRL 4-5)	Technology Validation (TRL 6-7)	Commercial Production (TRL 8-9)	Market
Vaccine and Drug Delivery Platforms						
Adaptable self-cleaving VLP vaccines	Self-cleaving platform for generation of VLP vaccines against enveloped RNA viruses.					
Liquid crystalline nanoparticles	Lipid-based cubosomes and hexosomes for mRNA delivery with improved RNA loading efficiency and higher endosome escape properties.					
Selective Organ Targeting	mRNA delivery platform capable of being tuned to target selective organs, including the brain.					
Radiopharmaceutical Technologies						
Antibody pre-targeting for diagnostic imaging	Diagnostic imaging of neurodegenerative diseases by antibody pre-targeting of plaques and tangles.					

For further information regarding any of these assets, please contact the Knowledge and Technology Transfer team:
go.unimelb.edu.au/za4p | ip-mailbox@unimelb.edu.au

The University of Melbourne (Australian University) PRV12150 / CRICOS 00116K